The ever-improving technology to generate induced pluripotent stem cells (iPSCs) has
increased their potential use as novel candidates for disease modeling, drug screening …

Induced pluripotent stem cells (iPSCs) were first described in 2006 and have since emerged
as a promising cell source for clinical applications. The rapid progression in iPSC …

Abstract Purpose of Review The goal of this paper is to highlight the major challenges in the
translation of human pluripotent stem cells into a clinical setting. Recent Findings Innate …

The isolation of embryonic stem cells (ESCs) has furthered our understanding of normal
embryonic development and fueled the progression of stem cell derived therapies. However …

The promise of human induced pluripotent stem cells (iPSCs) lies in their ability to serve as
a starting material for autologous, or patient‐specific, stem cell–based therapies. Since the …

Reprograming somatic cells using exogenetic gene expression represents a
groundbreaking step in regenerative medicine. Induced pluripotent stem cells (iPSCs) are …

Derivation of human embryonic stem cell (hES) lines in 1998 was not only a major
technological breakthrough in the field of regenerative medicine; it also triggered a …

Recently, induced pluripotent stem cells (iPSCs) were established as promising cell sources
for revolutionary regenerative therapies. The initial culture system used for iPSC generation …

Recently, there has been a major uptick in the research and clinical development of
pluripotent stem cells (PSCs). This is due to human PSC's unique properties of unlimited self …

Human embryonic stem cells (hESCs), initially thought to be immune privileged cells, are
now known to be susceptible to immune recognition. Human induced pluripotent stem cells …